Home Immunology & Inflammation Fungal Inhibitor Cycloheximide

nur für Forschungszwecke

Cycloheximide Proteinsynthesehemmer

Kat.-Nr.S7418

Cycloheximide, ein antimykotisches Antibiotikum, ist ein Eukaryoten-Proteinsynthesehemmer mit einer IC50 von 532,5 nM bzw. 2880 nM für die Proteinsynthese und RNA-Synthese in vivo. Cycloheximide unterdrückt Ferroptose und hemmt die Autophagie.Cycloheximide (NSC-185) kann verwendet werden, um Tiermodelle von Dysmnesie zu induzieren.Lösungen sind instabil und sollten frisch zubereitet werden.Dieses Produkt ist eine gefährliche Chemikalie (akute Toxizität/entzündlich/hautätzend). Bitte verwenden Sie es mit Schutzmaske, Handschuhen und Schutzkleidung.
Cycloheximide Fungal Inhibitor Chemical Structure

Chemische Struktur

Molekulargewicht: 281.35

Springe zu

Qualitätskontrolle

Charge: Reinheit: 99.96%
99.96

Zellkultur, Behandlung & Arbeitskonzentration

Zelllinien Assay-Typ Konzentration Inkubationszeit Formulierung Aktivitätsbeschreibung PMID
CEM Anticancer assay Tested in vitro for anticancer activity against CEM cells, IC50 = 0.12 μM. 10072683
9L Anticancer assay Tested in vitro for anticancer activity against 9L cells, IC50 = 0.2 μM. 10072683
SK-MEL-28 Anticancer assay Tested in vitro for anticancer activity against SK-MEL-28 cells, IC50 = 1 μM. 10072683
Vero Cytotoxicity assay Tested in vitro for cytotoxicity against Vero cells, IC50 = 1.2 μM. 10072683
LNCaP Anticancer assay Tested in vitro for anticancer activity against LNCaP cells, IC50 = 1.2 μM. 10072683
MCF-7 Anticancer assay Tested in vitro for anticancer activity against MCF-7 cells, IC50 = 1.5 μM. 10072683
PBM Cytotoxicity assay Tested in vitro for cytotoxicity against PBM cells, IC50 = 2.1 μM. 10072683
HepG2 Anticancer assay Tested in vitro for anticancer activity against HepG2 cells, IC50 = 2.5 μM. 10072683
SK-MES-1 Anticancer assay Tested in vitro for anticancer activity against SK-MES-1 cells, IC50 = 2.7 μM. 10072683
PC-3 Anticancer assay Tested in vitro for anticancer activity against PC-3 cells, IC50 = 3.5 μM. 10072683
Jurkat T-cells Function assay Inhibitory concentration against Human Jurkat T cells, IC50 = 0.93 μM. 10212121
Jurkat T-cells Function assay Inhibitory concentration against Human Jurkat T cells, IC80 = 1.54 μM. 10212121
Jurkat T-cells Function assay 48 hours Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC50 = 0.93 μM. 11052798
Jurkat T-cells Function assay 48 hours Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC80 = 1.54 μM. 11052798
CEM Cytotoxicity assay Cytotoxicity was determined in CEM cells, relative to RVT, IC50 = 0.08 μM. 15081000
PBM Cytotoxicity assay Cytotoxicity was determined in PBM cells, relative to RVT, IC50 = 0.46 μM. 15081000
Vero Cytotoxicity assay Cytotoxicity was determined in Vero cells, relative to RVT, IC50 = 0.53 μM. 15081000
HeLa Function assay Inhibition of hypoxia-induced HIF1 activation in human HeLa cells by luciferase reporter gene assay, IC50 = 0.036 μM. 15974627
medulloblastoma cells Antiproliferative assay Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay, EC50 = 0.042 μM. 17417631
neural precursor cells Antiproliferative assay Antiproliferative activity against mouse neural precursor cells by colony formation assay, EC50 = 0.054 μM. 17417631
astrocyte cells Antiproliferative assay Antiproliferative activity against mouse astrocyte cells by MTT assay, EC50 = 0.071 μM. 17417631
neural precursor cells Antiproliferative assay Antiproliferative activity against mouse neural precursor cells by MTT assay, EC50 = 0.142 μM. 17417631
HeLa Cytotoxicity assay 24 hrs Cytotoxicity against human HeLa cells after 24 hrs, CD50 = 0.1 μM. 18394884
3T3 Cytotoxicity assay 72 hrs Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.912 μM. 18771242
HeLa Function assay 2 hrs Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy, IC50 = 0.5325 μM. 20118940
HeLa Function assay 2 hrs Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting, IC50 = 2.8801 μM. 20118940
3T3 Cytotoxicity assay 72 hrs Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. 20356064
BESM Function assay 88 hrs Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay, EC50 = 0.4 μM. 20547819
NIH/3T3 Cytotoxicity assay 48 hrs Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay, IC50 = 1.1 μM. 21899268
MDA-MB-231 Cytotoxicity assay 48 hrs Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 1.2 μM. 21899268
AGS Cytotoxicity assay 48 hrs Cytotoxicity against human AGS cells after 48 hrs by MTT assay, IC50 = 3.6 μM. 21899268
HT-29 Cytotoxicity assay 48 hrs Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay, IC50 = 12.8 μM. 21899268
HepG2-A16-CD81 Function assay 10 uM NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration, IC50 = 0.0781 μM. 22096101
3T3 Cytotoxicity assay 72 hrs Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. 22437110
HepG2 Function assay HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells, IC50 = 0.047 μM. 22586124
PA1 Cytotoxicity assay 24 hrs Cytotoxicity against human PA1 cells after 24 hrs by MTT assay, IC50 = 40.6 μM. 23202484
PA1 Growth inhibition assay 24 hrs Growth inhibition of human PA1 cells after 24 hrs by MTT assay, IC50 = 40.6 μM. 28011220
3T3 Cytotoxicity assay Cytotoxicity against mouse 3T3 cells by SRB assay, IC50 = 0.3 μM. 29247859
CEM Cytotoxicity assay 5 days Cytotoxicity against human CEM cells assessed as decrease in cell viability after 5 days by MTT assay, IC50 = 0.2 μM. 29778528
Vero Cytotoxicity assay 3 days Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 3 days by MTT assay, IC50 = 0.2 μM. 29778528
3T3 Cytotoxicity assay 48 hrs Cytotoxicity against rat 3T3 cells after 48 hrs by MTT assay, IC50 = 0.61 μM. 30146096
MCF7 Function assay 10 ug/mL 1 hr Inhibition of HIF1alpha RNA translation in human MCF7 cells at 10 ug/mL pretreated for 1 hr prior to metabolic labeling by SDS-PAGE analysis 22607231
AGS Apoptosis assay 150 ug/mL 48 hrs Induction of apoptosis in human AGS cells assessed as early apoptosis level at 150 ug/mL after 48 hrs by Annexin V-FITC apoptosis assay 21899268
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells 29435139
T47D Function assay 10 uM 4 hrs Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting 15974627
T47D Function assay 0.3 uM 4 hrs Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting 15974627
T47D Function assay 3 uM 16 hrs Inhibition of hypoxia-induced HIF1 activation in human T47D cells at 3 uM after 16 hrs by luciferase reporter gene assay 15974627
T47D Function assay 0.7 uM 16 hrs Inhibition of 1,10-phenanthroline-induced HIF1 activation in human T47D cells at 0.7 uM after 16 hrs by luciferase reporter gene assay 15974627
T47D Function assay 10 uM 16 hrs Inhibition of hypoxia-induced VEGF expression in human T47D cells at 10 uM after 16 hrs by ELISA 15974627
T47D Function assay 0.3 uM 4 hrs Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting 15974627
T47D Function assay 10 uM 4 hrs Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting 15974627
neural precursor cells Function assay 3 uM Induction of neurosphere phenotype changes in mouse neural precursor cells at 3 uM 17417631
HeLa Cytotoxicity assay Cytotoxicity against human HeLa cells assessed as inhibition of DNA replication by imaging analysis 18066055
HeLa Function assay Inhibition of mitosis in human HeLa cells by imaging analysis 18066055
HEK293T Function assay 50 uM 30 mins Effect on polyribosome profiling in human HEK293T cells assessed as depletion of polysomes at 50 uM after 30 mins by spectrophotometry 20118940
T47D Antiproliferative assay 10 uM 48 hrs Antiproliferative activity against human T47D cells at 10 uM after 48 hrs by SRB assay 23434131
MDA-MB-231 Antiproliferative assay 10 uM 48 hrs Antiproliferative activity against human MDA-MB-231 cells at 10 uM after 48 hrs by SRB assay 23434131
NCI-H460 Function assay 10 ug/mL up to 9 hrs Reduction of HSP1 stability in human NCI-H460 cells assessed as protein degradation at 10 ug/mL up to 9 hrs by Western blot analysis 24746225
HeLa Cytotoxicity assay 25 uM 18 hrs Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 25 uM after 18 hrs by inverse MTT assay 25028062
RAW264.7 Function assay 70 uM 6 hrs Inhibition of luminescence emission in mouse RAW264.7 cells transfected with luciferase plasmid containing universal promoter PKG at 70 uM after 6 hrs by luciferase reporter gene assay 25667960
Klicken Sie hier, um weitere experimentelle Daten zu Zelllinien anzuzeigen

Chemische Informationen, Lagerung & Stabilität

Molekulargewicht 281.35 Formel

C15H23NO4

 Lagerung (Ab dem Eingangsdatum) 3 years-20°C powder
CAS-Nr. 66-81-9 -- Lagerung von Stammlösungen

Synonyme NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80 Smiles CC1CC(C(=O)C(C1)C(CC2CC(=O)NC(=O)C2)O)C

Löslichkeit

In vitro
Charge:

DMSO : 56 mg/mL (199.04 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Ethanol : 56 mg/mL

Water : 15 mg/mL

Molaritätsrechner

Masse Konzentration Volumen Molekulargewicht
Verdünnungsrechner Molekulargewichtsrechner

In vivo
Charge:

In-vivo-Formulierungsrechner (Klare Lösung)

Schritt 1: Geben Sie die untenstehenden Informationen ein (Empfohlen: Ein zusätzliches Tier zur Berücksichtigung von Verlusten während des Experiments)

mg/kg g μL

Schritt 2: Geben Sie die In-vivo-Formulierung ein (Dies ist nur der Rechner, keine Formulierung. Bitte kontaktieren Sie uns zuerst, wenn es im Abschnitt "Löslichkeit" keine In-vivo-Formulierung gibt.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Berechnungsergebnisse:

Arbeitskonzentration: mg/ml;

Methode zur Herstellung der DMSO-Stammlösung: mg Wirkstoff vorgelöst in μL DMSO ( Konzentration der Stammlösung mg/mL, Bitte kontaktieren Sie uns zuerst, wenn die Konzentration die DMSO-Löslichkeit der Wirkstoffcharge überschreitet. )

Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügenμL PEG300, mischen und klären, dann hinzufügenμL Tween 80, mischen und klären, dann hinzufügen μL ddH2O, mischen und klären.

Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügen μL Maisöl, mischen und klären.

Hinweis: 1. Bitte stellen Sie sicher, dass die Flüssigkeit klar ist, bevor Sie das nächste Lösungsmittel hinzufügen.
2. Achten Sie darauf, das/die Lösungsmittel der Reihe nach hinzuzufügen. Sie müssen sicherstellen, dass die bei der vorherigen Zugabe erhaltene Lösung eine klare Lösung ist, bevor Sie mit der Zugabe des nächsten Lösungsmittels fortfahren. Physikalische Methoden wie Vortex, Ultraschall oder ein heißes Wasserbad können zur Unterstützung des Lösens verwendet werden.

Wirkmechanismus

In vitro

Cycloheximid, ein Proteinsynthesehemmer, reduziert den durch GSIV induzierten Tod der Wirtszelle, indem es die Phosphatidylserin-Exposition und den Verlust von ΔΨm durch Apoptose/Nekrose abschwächt.
In vivo

Diese Verbindung, ein Proteinsynthesehemmer, wirkt auf das Gedächtnis, indem sie als sekundäre Folge der Hemmung der Proteinsynthese die Modulatoren der Gedächtnisbildung verändert.
Literatur
  • [4] https://pubmed.ncbi.nlm.nih.gov/30916348/

Anwendungen

Methoden Biomarker Bilder PMID
Western blot β-catenin / MSX2 LIFR / gp130 / TfR BIP / P-P70S6K / P62 / ATF4 / Actin / LC3-I / LC3-II CYP87A3 ERK3 / IRP2
S7418-WB-1
12095419
RNA blot PDI-2 / tubulin / rRNA LEF1 / Cyc-D1 / IGF-1 / HGF / VEGF / KGF / GAPDH
S7418-RNA-1
18713834
Immunofluorescence SCD6 / DHH1 / XRNA α-eIF3 / α-Dcp1 TUNEL Rpl25 / Nhp6 β-Catenin
S7418-IF-1
18713834

Klinische Studieninformationen

(Daten von https://clinicaltrials.gov, aktualisiert am 2024-05-22)

NCT-Nummer Rekrutierung Erkrankungen Sponsor/Kooperationspartner Startdatum Phasen
NCT03700788 Not yet recruiting
Apical Periodontitis
University of Southern California
 May 30 2023 Phase 3
NCT05506566 Recruiting
Tumor|Positron-Emission Tomography
First Affiliated Hospital of Fujian Medical University
 May 1 2022 Phase 1|Phase 2
NCT02202304 Withdrawn
Periodontal Disease|Caries
Rosa Moreno Lopez|Ivoclar Vivadent AG|University of Aberdeen
 September 10 2017 Phase 4
NCT01521325 Completed
Mesothelioma|Pancreatic Cancer|Ovarian Cancer|Non-small Cell Lung Cancer
Morphotek
 September 2011 Phase 1
NCT02168374 Completed
Dental Caries
Aline R F de Castilho|Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Campinas Brazil
 March 2008 Phase 2

Technischer Support

Handhabungshinweise

Tel: +1-832-582-8158 Ext:3

Wenn Sie weitere Fragen haben, hinterlassen Sie bitte eine Nachricht.

Bitte geben Sie Ihren Namen ein.
Bitte geben Sie Ihre E-Mail-Adresse ein. Bitte geben Sie eine gültige E-Mail-Adresse ein.
Bitte schreiben Sie uns etwas.